Beijing Konruns Pharmaceutical Co., Ltd.SSE: 603590

(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Receipt of Clinical Trial Approval Notice for KC1086 Combined with Fulvestrant for the Treatment of HR+HER2- Locally Advanced or Metastatic Breast Cancer

· Issued by Beijing Konruns Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 603590 · · 2 pages · Chinese

Summary by 6ix AI

The approval was granted by the National Medical Products Administration, allowing the company to proceed with clinical research on this combination therapy. The announcement includes a risk warning regarding the uncertainties associated with drug development and its potential impact on the company's performance.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/603590beijing-konruns-pharmaceutical-co-ltdannouncement-on-receipt-of-clinical-trial-approval-notice-for-kc1086-combined-with-fulvestrant-for-the-treatment-of-hrher2-locally-advanced-or-metastatic-breast-cancer

Release

Announcement on Receipt of Clinical Trial Approval Notice for KC1086 Combined with Fulvestrant for the Treatment of HR+HER2- Locally Advanced or Metastatic Breast Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Beijing Konruns Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Beijing Konruns Pharmaceutical

All Beijing Konruns Pharmaceutical news releases